Literature DB >> 17372278

Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma.

David C Hodgson1, Ethel S Gilbert, Graça M Dores, Sara J Schonfeld, Charles F Lynch, Hans Storm, Per Hall, Froydis Langmark, Eero Pukkala, Michael Andersson, Magnus Kaijser, Heikki Joensuu, Sophie D Fosså, Lois B Travis.   

Abstract

PURPOSE: Hodgkin's lymphoma (HL) survivors are known to be at substantially increased risk of solid cancers (SC). However, no investigation has used multivariate modeling to estimate the relative risk (RR), excess absolute risk (EAR), and cumulative incidence for specific attained ages and ages at HL diagnosis. PATIENTS AND METHODS: We identified 18,862 5-year HL survivors from 13 population-based cancer registries in North America and Europe. Poisson regression was used to evaluate the effects of age at diagnosis, attained age, latency, sex, treatment, and year of diagnosis on the RR and EAR of SC.
RESULTS: Among 1,490 identified SC, 850 were estimated to be in excess. For most cancer sites, both RR and EAR decreased with age at HL diagnosis and showed strong dependencies on attained age. For a patient diagnosed at age 30 years and survived to > or = 40 years, modeled risks were significantly elevated for cancers of the breast (RR = 6.1), other supradiaphragmatic sites (RR = 6.0), and infradiaphragmatic sites (RR = 3.7); the largest RR (20-fold) was observed for malignant mesothelioma. Thirty-year cumulative risks of SC for men and women diagnosed at 30 years were 18% and 26%, respectively, compared with 7% and 9%, respectively, in the general population. For young HL patients, risks of breast and colorectal cancers were elevated 10 to 25 years before the age when routine screening would be recommended in the general population.
CONCLUSION: Multivariable modeling demonstrates for the first time temporal changes in SC risk not evident in unadjusted analyses, and can facilitate the development of individualized risk assessment and the creation of screening strategies for early detection.

Entities:  

Mesh:

Year:  2007        PMID: 17372278     DOI: 10.1200/JCO.2006.09.0936

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  105 in total

1.  Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study.

Authors:  Paul Craig Nathan; Kirsten Kimberlie Ness; Martin Christopher Mahoney; Zhenghong Li; Melissa Maria Hudson; Jennifer Sylene Ford; Wendy Landier; Marilyn Stovall; Gregory Thomas Armstrong; Tara Olive Henderson; Leslie L Robison; Kevin Charles Oeffinger
Journal:  Ann Intern Med       Date:  2010-10-05       Impact factor: 25.391

Review 2.  Appropriate surveillance for late complications in patients in remission from Hodgkin lymphoma.

Authors:  Deborah L Darrington; Julie M Vose
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

Review 3.  State-of-the-art issues in Hodgkin's lymphoma survivorship.

Authors:  Shrujal S Baxi; Matthew J Matasar
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

Review 4.  Consolidative Radiation in DLBCL: Evidence-Based Recommendations.

Authors:  David C Hodgson; N George Mikhaeel
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

5.  Ionizing radiation exposure as a result of diagnostic imaging in patients with lymphoma.

Authors:  M P Crowley; S B O'Neill; B Kevane; D C O'Neill; J A Eustace; M R Cahill; B Bird; M M Maher; K O'Regan; D O'Shea
Journal:  Clin Transl Oncol       Date:  2015-08-26       Impact factor: 3.405

6.  Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.

Authors:  David Sibon; Franck Morschhauser; Matthieu Resche-Rigon; David Ghez; Jehan Dupuis; Ambroise Marçais; Bénédicte Deau-Fischer; Reda Bouabdallah; Catherine Sebban; Gilles Salles; Pauline Brice
Journal:  Haematologica       Date:  2015-12-31       Impact factor: 9.941

7.  Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.

Authors:  Didier Jean; Emilie Thomas; Elodie Manié; Annie Renier; Aurélien de Reynies; Céline Lecomte; Pascal Andujar; Jocelyne Fleury-Feith; Françoise Galateau-Sallé; Marco Giovannini; Jessica Zucman-Rossi; Marc-Henri Stern; Marie-Claude Jaurand
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 8.  Second malignant neoplasms and cardiovascular disease following radiotherapy.

Authors:  Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice
Journal:  J Natl Cancer Inst       Date:  2012-02-06       Impact factor: 13.506

Review 9.  Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.

Authors:  Annette E Hay; Ralph M Meyer
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

Review 10.  Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.

Authors:  Jeremy Franklin; Dennis A Eichenauer; Ingrid Becker; Ina Monsef; Andreas Engert
Journal:  Cochrane Database Syst Rev       Date:  2017-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.